PMID: 9533175Apr 9, 1998Paper

Mechanism of the neuroleptic-induced obesity in female rats

Progress in Neuro-psychopharmacology & Biological Psychiatry
T BaptistaL Hernández

Abstract

1. Obesity is an undesirable side effect of neuroleptics which affects 50% approximately of patients under a program of chronic administration. 2. An animal model of neuroleptic-induced obesity and hyperphagia has been developed in female rats treated chronically with sulpiride (20 mg/Kg/ip. for 21 days). However, it is unknown whether or not the hyperphagia is essential for the development of this type of obesity. 3. Sulpiride or vehicle was administered in two experimental conditions: in the first one, food was available in an amount which was three times the previous individual daily food intake; in the second one, the daily food provision was maintained at the individual daily average before starting the treatments. This way hyperphagia was prevented in half of the groups. Besides the body weight gain measurement in all the groups, the serum levels of estradiol, prolactin, glucose and lipids were assessed in the groups with unrestricted food intake. 4. Food restriction prevented the sulpiride-induced weight gain, even though the rats displayed a permanent diestrus which suggests an hyperprolactinemia-induced impairment in the balance of the reproductive hormones that may promote weight gain. However, the basal levels of est...Continue Reading

References

Jan 1, 1977·European Journal of Clinical Pharmacology·G ErleC Scandellari
Apr 1, 1975·Journal of Psychiatric Research·R G RobinsonM F Folstein
Jan 1, 1992·Neuroscience and Biobehavioral Reviews·G N Wade, J E Schneider
Oct 1, 1990·Pharmacology, Biochemistry, and Behavior·T BaptistaB G Hoebel
May 1, 1989·Pharmacology, Biochemistry, and Behavior·M A ParadaM de Quijada
Apr 1, 1987·Journal of Clinical Psychopharmacology·N CorreaB Birmaher
Oct 5, 1988·Neuroscience Letters·T BaptistaE Murzi
Aug 1, 1988·Pharmacology, Biochemistry, and Behavior·M A ParadaB G Hoebel
Feb 1, 1985·Experimental and Molecular Pathology·M P JokinenR W Prichard
Apr 16, 1981·Nature·J Dorrington, R E Gore-Langton
Mar 1, 1995·Pharmacopsychiatry·T BaptistaL Hernàndez
Jan 1, 1994·Psychoneuroendocrinology·R D Oades, R Schepker
May 1, 1993·Pharmacology, Biochemistry, and Behavior·T BaptistaL Hernández

❮ Previous
Next ❯

Citations

Mar 22, 2005·Psychopharmacology·G D CooperA J Goudie
Jul 11, 2002·European Journal of Pharmacology·Trino BaptistaSerge Beaulieu
May 22, 2003·Pharmacology, Biochemistry, and Behavior·B PouzetS Velschow
Nov 1, 2003·Pharmacology, Biochemistry, and Behavior·Abegale W HartfieldPeter G Clifton
Mar 18, 1999·Pharmacology, Biochemistry, and Behavior·T BaptistaL Hernández
Jun 16, 1999·Progress in Neuro-psychopharmacology & Biological Psychiatry·T BaptistaL Hernández
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Trino BaptistaMaritza Martinez
Aug 12, 1999·Acta Psychiatrica Scandinavica·T Baptista
Sep 16, 2010·BMC Psychiatry·Michael CaseVicki Poole Hoffmann
Jan 1, 2011·Schizophrenia Research and Treatment·Fabio PanarielloAndrea de Bartolomeis
Jun 20, 2006·Psychopharmacology·Julie Minet-RinguetRenaud de Beaurepaire
Feb 13, 2001·Acta Psychiatrica Scandinavica·T Baptista
Oct 16, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jing ZuoXiao-Hong Lu
May 15, 2007·Physiology & Behavior·Barbara Woodside
Apr 23, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Martien WampersMarc De Hert
Dec 31, 2002·Journal of Psychopharmacology·Andrew J GoudieJason C G Halford
Mar 30, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M B CopeD B Allison
Jan 5, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·T BaptistaL Hernàndez
May 8, 2019·Reviews in Endocrine & Metabolic Disorders·Luis G Sobrinho, Nelson D Horseman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.